Navigation Links
Amylin Pharmaceuticals to Present at the Bank of America 2011 Healthcare Conference
Date:5/5/2011

SAN DIEGO, May 5, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Bank of America 2011 Healthcare Conference on Thursday, May 12, 2011 at 3:30 p.m. ET / 12:30 p.m. PT in Las Vegas. David Maggs, M.D., vice president, medical research and development at Amylin Pharmaceuticals, will provide a corporate overview.

The presentation will be webcast live through the "Investors" section of Amylin's corporate website at www.amylin.com, and a recording will be made available on the website following the event. To access the live webcast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information about Amylin Pharmaceuticals is available at www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
6. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
7. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
8. Amylin Pharmaceuticals to Webcast Year-End Financial Results
9. Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference
10. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
11. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , 11. Juli 2014  Dilon ... für die molekulare Bildgebung, einschließlich molekularer ... die CE-Zulassung für sein Navigator ® ... Dilon das Produkt jetzt europaweit vertreiben. ... Großteil der europäischen Länder ausgedehnt und ...
(Date:7/10/2014)... 2014  RESMED INC. (NYSE: RMD ) today ... year ended June 30, 2014 results on Thursday, July 31, ... press release with ResMed,s results will be issued after 1:00 ... webcast to discuss operating results and future outlook. ... US Pacific Time and the live webcast of the call ...
(Date:7/10/2014)... July 10, 2014   Ventana Medical Systems, Inc. ... it has entered into an agreement with Merck KGaA, ... EMD Serono in the United States ... with Merck KGaA,s biopharmaceutical division on the development and ... target using Ventana,s proprietary diagnostic assays. In alignment with ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... June 4 Mylan Inc. (Nasdaq: MYL ) ... approval from the U.S. Food and Drug Administration (FDA) for its ... and 800 mg, the generic version of Pfizer,s Neurontin® Tablets for ... will be distributed by Mylan Pharmaceuticals Inc. , ...
... June 4 Syndax Pharmaceuticals, Inc., a ... Phase 2, open-label ENCORE 303 trial in post-menopausal women ... were progressing on aromatase inhibitor (AI) therapy. Safety and ... a poster at the American Society of Clinical Oncology ...
Cached Medicine Technology:Mylan Receives Approval for Generic Version of Neurontin® Tablets 2Syndax Pharmaceuticals' Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer 2Syndax Pharmaceuticals' Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer 3Syndax Pharmaceuticals' Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer 4
(Date:7/11/2014)... records to understand the best available treatment for patients, ... and less costly for taxpayers than the existing clinical ... Professor van Staa, carried out while he was a ... who is now based at The University of Manchester,s ... ( HTA ) today (Friday 11 July) looked ...
(Date:7/11/2014)... HealthDay Reporter THURSDAY, July 10, ... the risk for stroke, a new study suggests. The ... a stroke or a transient ischemic attack (TIA) by ... or TIA risk by 59 percent. And hostility doubled the ... by a temporary blockage of blood flow to the brain. ...
(Date:7/11/2014)... conducted at Aarhus University has revealed that people who ... only half as likely as their urban counterparts to ... and Crohn,s disease. The study findings have recently been ... , "It is extremely exciting that we can now ... classic inflammatory diseases appear to depend on the environment ...
(Date:7/11/2014)... As reported by Forbes in the article Robert Downey ... (6/30), Indino Downey has reportedly been arrested after being ... with. His father, well-known actor Robert Downey Jr. believes ... may have something to do with his addiction struggles. ... and 1990s for substance abuse before finally getting clean ...
(Date:7/11/2014)... July 11, 2014 Having experienced mental illness ... member of mental hospital staff, Roger Grainger gives readers an ... in his new book, “You Never Get Out.” , According ... the United Kingdom will experience some kind of mental health ... still needs to take a look at the way mental ...
Breaking Medicine News(10 mins):Health News:Better use of electronic health records makes clinical trials less expensive 2Health News:Stress, Depression May Boost Stroke Risk, Study Finds 2Health News:Stress, Depression May Boost Stroke Risk, Study Finds 3Health News:Growing up on a livestock farm halves the risk of inflammatory bowel diseases 2Health News:Roberty Downey's Son Arrested For Cocaine 2Health News:Psychiatric Hospital Patient and Registered Psychologist Explores Mental Health and Therapy in New Book "You Never Get Out" 2
... for "tennis elbow" but needs to be injected properly ... CMAJ ( Canadian Medical Association Journal ) ... a randomized controlled trial of 48 patients, was performed ... University of Medical Sciences that serves patients from all ...
... HACKENSACK, N.J. (April 26, 2010, 4 p.m. EDT) Myelodysplastic syndromes ... are nearly five times more common in seniors than previously ... John Theurer Cancer Center at Hackensack University Medical Center. ... patients are at much higher risk for heart attack, diabetes ...
... predict which are most likely to be good candidates ... News) -- U.S. researchers have developed a new tool ... potential organ donors, a development that could potentially boost ... damage are often good candidates for organ donation when ...
... diabetes now widespread, CDC survey finds , MONDAY, April ... adults have either high blood pressure, high cholesterol or ... stroke and other cardiovascular problems, a new government survey ... Health and Nutrition Examination Survey (NHANES) 1999-2006 shows that ...
... VA - The American Society of Pediatric Otolaryngology (ASPO) ... 2, during the 2010 Combined Otolaryngology Spring Meetings (COSM) ... Las Vegas, NV. During the ASPO meeting, ... scientific sessions featuring expert panelists will be presented focusing ...
... Readers are ... his interest and research on improving ones state of life. This book helps readers to ... strives to touch all walks of life. , ... Washington, D.C. (Vocus) April 26, 2010 -- Thomas Finn is ...
Cached Medicine News:Health News:Botulinum injection provides relief of tennis elbow 2Health News:MDS, a blood cancer, strikes nearly 5 times more Americans than previously thought 2Health News:MDS, a blood cancer, strikes nearly 5 times more Americans than previously thought 3Health News:Test Spots Potential Organ Donors Among Coma Patients 2Health News:Nearly Half of U.S. Adults Have Heart Risk Factors 2Health News:Nearly Half of U.S. Adults Have Heart Risk Factors 3Health News:Scientific meeting will host new research in children's ear, nose and throat health 2Health News:Life Coach and Author Thomas Finn's Highly Anticipated Book, 'A Better Tomorrow- Affirmations and Visualizations the Keys to Success,' Debuts June 15 2
... of automatic systems for performing erythrocyte sedimentation ... blood. With the introduction of the Ves-matic ... market a truly revolutionary testing system which ... with the traditional ESR techique.,By means of ...
... VACUETTE® erythrocyte sedimentation rate analysers, which ... new generation unites the well-established advantages ... range of additional innovations which guarantee ... sedimentation rate. Cost effectiveness is an ...
... ESR analyzer that brings about ... pipettes. Up to 40 test ... or bach, with automated mixing. ... for back-up support or to ...
The Sedimat 15 Automated sedrate system provides an accurate ESR result in only 15 minutes. Fast, in-office results (before patient leaves the office) can lead to improved patient therapy....
Medicine Products: